| Not Yet Recruiting | A Phase 1/2 Study of Personalized PSMA Radiopharmaceutical Therapy NCT05896371 | CHU de Quebec-Universite Laval | Phase 1 / Phase 2 |
| Not Yet Recruiting | PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan NCT07484269 | Novartis Pharmaceuticals | — |
| Not Yet Recruiting | Dapagliflozin Combined With Next-generation Hormonal Agent (NHA) Versus Single NHA in Participants With Metast NCT07310433 | Yung NA | Phase 2 |
| Not Yet Recruiting | First-in-Human Study to Evaluate AZD8359 STEAP2 TCE in Participants With Prostate Cancer NCT07529717 | AstraZeneca | Phase 1 / Phase 2 |
| Recruiting | 177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer NCT07145177 | University of California, San Francisco | Phase 1 |
| Not Yet Recruiting | ACTinium in Castrate-RESistant Prostate Cancer After LUTEtium NCT07414940 | University College, London | Phase 1 / Phase 2 |
| Not Yet Recruiting | Low Dose Naltrexone (LDN) for Management of Fatigue in Prostate Cancer Patients on Androgen Deprivation Therap NCT07224009 | University of Arkansas | Phase 2 |
| Recruiting | Real-world Use of Lutetium (177Lu) Vipivotide Tetraxetan in China(PSMAreal CN) NCT07290270 | Novartis Pharmaceuticals | — |
| Recruiting | Evaluating Dose Timing (Morning vs Evening) of Endocrine-based Therapies in Metastatic Breast and Prostate Can NCT07252726 | Ottawa Hospital Research Institute | Phase 4 |
| Recruiting | Pharmaceutical Management in Targeted Radioligand Therapy NCT07389512 | Hospices Civils de Lyon | — |
| Recruiting | Physician- and Patient-based Barriers to NGS Testing NCT07209176 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | N/A |
| Not Yet Recruiting | CONVERT-HB1: Radical Prostatectomy After Systemic Therapy for High-volume Metastatic Hormone-sensitive Prostat NCT07268794 | Fudan University | Phase 2 |
| Recruiting | Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer NCT07181161 | AstraZeneca | Phase 1 / Phase 2 |
| Recruiting | Comparison of Different Methods of CAPTure of Circulating Tumour Cells (CTC) in Patients With Metastatic Breas NCT06904625 | Institut Claudius Regaud | N/A |
| Recruiting | A Study of Tarlatamab for People With Prostate Cancer NCT07111507 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Recruiting | Cabazitaxel +/- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate Cancer NCT06738303 | Case Comprehensive Cancer Center | Phase 2 |
| Recruiting | 7-Days Water-Only Fasting Trial in Prostate Cancer NCT06826924 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | N/A |
| Recruiting | Impact of Multimodal Telerehabilitation in Rural Patients With Metastatic Prostate Cancer NCT07032584 | University of Utah | N/A |
| Recruiting | Clinical Study of Safety and Efficacy of Universal PSMA CAR- T in Refractory CRPC NCT06895811 | Shanghai Changzheng Hospital | Phase 1 |
| Recruiting | Prostate Cryoablation Combined With Metronomic Cyclophosphamide for Metastatic Prostate Cancer NCT06854250 | Sun Yat-sen University | Phase 2 |
| Recruiting | Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients NCT06616597 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 |
| Recruiting | A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab NCT06782555 | ImmunoGenesis | Phase 1 / Phase 2 |
| Recruiting | Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients With Alterations in DNA Damage NCT06439225 | Canadian Cancer Trials Group | Phase 3 |
| Recruiting | 18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prost NCT06706921 | VA Greater Los Angeles Healthcare System | Phase 4 |
| Terminated | A Dosimetry Study of Lutetium (177Lu) rhPSMA-10.1 and Lutetium (177Lu) Vipivotide Tetraxetan (Pluvicto®) in Pa NCT06516510 | Blue Earth Therapeutics Ltd | EARLY_Phase 1 |
| Active Not Recruiting | Exploiting Heterogeneity in Hormone Therapy Response to Reveal Early Determinants of Drug Resistance in Advanc NCT07352748 | Universita di Verona | — |
| Withdrawn | 177Lu-PSMA, Niraparib/AA Plus Prednisone for Prostate Cancer NCT06329830 | Baptist Health South Florida | Phase 1 / Phase 2 |
| Recruiting | Combination of TURP and Standard Systemic Therapy for MPCa NCT06655259 | Fudan University | Phase 2 |
| Completed | A Study of the Absorption, Distribution, Metabolism, and Elimination of Opevesostat (MK-5684) in Healthy Adult NCT06566989 | Merck Sharp & Dohme LLC | Phase 1 |
| Not Yet Recruiting | A Journey Into Participation Patterns Among Metastatic Prostate Cancer Patients NCT06009549 | Power Life Sciences Inc. | — |
| Recruiting | Remotely Monitored Exercise Interventions in Patients with MCSPC Undergoing ADT (Prostate 006) NCT06429813 | Paul Viscuse | N/A |
| Recruiting | Talazoparib Plus Enzalutamide After Progression to Abiraterone in Metastatic Prostate Cancer: (TEAM PC) NCT06582628 | Fundacion Oncosur | Phase 2 |
| Active Not Recruiting | PSMAtrack-tracking Changes in PSMA-PET During Initial Therapy for Metastatic Hormone-sensitive Prostate Cancer NCT06479187 | Brigham and Women's Hospital | Phase 4 |
| Recruiting | The Effect of a Structured Strength and Endurance Training Program on Quality of Life, Fitness, Blood Paramete NCT07126860 | Ludwig-Maximilians - University of Munich | N/A |
| Active Not Recruiting | LuCarbo - a Study of 177Lu-PSMA-617 Plus Carboplatin in Metastatic Castrate-resistant Prostate Cancer NCT06303713 | Dana-Farber Cancer Institute | Phase 1 |
| Completed | Evaluate Safety, Whole-Body Distribution and Radiation Dosimetry in Metastatic Castration Resistant Prostate C NCT06359821 | Sichuan University | EARLY_Phase 1 |
| Recruiting | Study of AZD0754 in Participants With Metastatic Prostate Cancer NCT06267729 | AstraZeneca | Phase 1 / Phase 2 |
| Recruiting | Pilot Study for Detection of PSMA-Low CRPC-NE Tumors With Fluciclovine PET/CT NCT06062745 | Brigham and Women's Hospital | Phase 1 |
| Recruiting | Debunking the Frailty-sarcopenIa-ADT Axis in mEtastatic Prostate canceR With multiComponent Exercise: The FIER NCT06040125 | Dana-Farber Cancer Institute | N/A |
| Recruiting | Intermittent Darolutamide Treatment in the Triple Therapy of mHSPC NCT06177015 | The First Affiliated Hospital with Nanjing Medical University | Phase 3 |
| Withdrawn | Adjuvant High-intensity Interval Training During Chemotherapy in Metastatic Prostate Cancer Patients NCT05156372 | The University of Texas Health Science Center at San Antonio | N/A |
| Recruiting | Creatine Supplementation and Resistance Training to Preserve Muscle Mass and Attenuate Cancer Progression NCT06112990 | University of Utah | Phase 3 |
| Withdrawn | Darolutamide With Radium-223 or Placebo and the Effect on Radiological Progression-Free Survival for Patients NCT05771896 | GenesisCare USA | Phase 3 |
| Terminated | The Present Study Aims to Compare Patients Who Receive the Investigational Product (177Lu-DOTA-rosopatamab) Pl NCT04876651 | Telix Pharmaceuticals (Innovations) Pty Ltd | Phase 3 |
| Active Not Recruiting | Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer NCT05617885 | Praful Ravi, MB BCHir, MRCP | Phase 1 |
| Recruiting | Comparing the Efficacy and Safety of Rezvilutamide+ADT+Docetaxel Versus Rezvilutamide +ADT in the mHSPC NCT05983783 | The First Affiliated Hospital with Nanjing Medical University | Phase 3 |
| Recruiting | Duration of Androgen Receptor Pathway Inhibitor and ADT With Metastasis Directed Therapy in Oligometastatic Ca NCT05404139 | University Health Network, Toronto | Phase 2 |
| Recruiting | TOward a comPrehensive Supportive Care Intervention for Older Men With Metastatic Prostate Cancer NCT05582772 | University Health Network, Toronto | N/A |
| Recruiting | A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Me NCT05800665 | Genentech, Inc. | Phase 1 |
| Not Yet Recruiting | Maximal Cytoreductive Therapies on Post-treatment Metastases in Pts With mHSPC During Apalutamide Plus ADT Tre NCT05717582 | Fudan University | Phase 2 |
| Recruiting | Measuring Oncological Value of Exercise and Statin NCT05796973 | Tampere University Hospital | Phase 3 |
| Recruiting | Feasibility and Impact of Liquid Biopsy Genomic Profiling on Treatment Patients With Metastatic Prostate Cance NCT05885009 | SOLTI Breast Cancer Research Group | — |
| Unknown | Study of 177Lu-PSMA-0057 in Metastatic Prostate Cancer NCT06050239 | Nanjing First Hospital, Nanjing Medical University | EARLY_Phase 1 |
| Recruiting | Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer NCT05751941 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Recruiting | The Impact of Radiotherapy on Oligometastatic Cancer NCT05933876 | Institut Investigacio Sanitaria Pere Virgili | — |
| Completed | Effects of Triptorelin Pamoate 6-month When Given to Adult Chinese Participants With Advanced Cancer in the Pr NCT05590793 | Ipsen | Phase 3 |
| Completed | Evaluation of the Technical Feasibility of Testing ct DNA for Homologous Recombination Gene Variants in Metast NCT05415787 | University Hospital, Tours | — |
| Active Not Recruiting | Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cance NCT05367440 | AstraZeneca | Phase 1 / Phase 2 |
| Recruiting | Study of ORIC-944 in Patients With Metastatic Prostate Cancer NCT05413421 | ORIC Pharmaceuticals | Phase 1 |
| Completed | MENCORE-2: Audio Recordings to Improve Decision-making in Advanced Prostate Cancer NCT05127850 | University of California, San Francisco | N/A |
| Recruiting | 68Ga-PSMA PET/CT for Ra223 Assessment NCT04951817 | Chang Gung Memorial Hospital | N/A |
| Unknown | The Study of Olaparib Combined With Abiraterone and Prednisone in mHSPC Patients With HRR Gene Mutation NCT05167175 | Hongqian Guo | Phase 2 |
| Completed | 177Lu-DOTA-TLX591 Safety, Biodistribution and Dosimetry Study NCT04786847 | Telix Pharmaceuticals (Innovations) Pty Limited | Phase 1 |
| Recruiting | Psma Intensity Can be Altered by Androgen and Phospho-SrC Obstruction NCT04925648 | St Vincent's Hospital, Sydney | Phase 2 |
| Recruiting | High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers NCT05011383 | VA Office of Research and Development | Phase 2 |
| Active Not Recruiting | Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide NCT04335682 | Alliance Foundation Trials, LLC. | Phase 2 |
| Completed | 64Cu-TLX592 Phase I Safety, PK, Biodistribution and Dosimetry Study (CUPID Study) NCT04726033 | Telix Pharmaceuticals (Innovations) Pty Limited | EARLY_Phase 1 |
| Recruiting | Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-direc NCT04787744 | VA Office of Research and Development | Phase 2 / Phase 3 |
| Active Not Recruiting | Phase Ia/Ib Talazoparib + Tazemetostat for mCRPC NCT04846478 | Dana-Farber Cancer Institute | Phase 1 |
| Unknown | The Effect of Metformin in Patients With Metastatic Castration-resistant Prostate Cancer NCT04926155 | Sun Yat-sen University | Phase 2 |
| Not Yet Recruiting | The Effect of Metformin in Patients With Newly Diagnosed mHSPC NCT04925063 | Sun Yat-sen University | Phase 2 |
| Active Not Recruiting | A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Pr NCT04709276 | Andrew J. Armstrong, MD | Phase 2 |
| Completed | TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate Cancer NCT04887506 | Tavanta Therapeutics | Phase 3 |
| Active Not Recruiting | ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate Cancer NCT04662580 | Janssen Research & Development, LLC | Phase 1 |
| Terminated | [18F]FLOR (FC303) PET/CT Imaging in Patients With Prostate Cancer NCT04528199 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 1 |
| Completed | Genetic Testing for Breast, Ovarian, Pancreatic, and Prostate Cancers NCT04330716 | Dana-Farber Cancer Institute | N/A |
| Recruiting | Management of Oligoprogressive Castration Resistant Prostate Cancer (PCS X) NCT04070209 | Sir Mortimer B. Davis - Jewish General Hospital | Phase 2 |
| Active Not Recruiting | Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC NCT04446117 | Exelixis | Phase 3 |
| Completed | Evaluation of Hypnosis in Virtual Reality on the Anxiety of Patients With Metastatic Prostate Cancer Over Chem NCT04533958 | Saint-Gregoire Private Hospital Center | N/A |
| Completed | mHealth ElectroNic COnsultation REcording (mENCORE) in Advanced Prostate Cancer NCT04545697 | University of California, San Francisco | N/A |
| Active Not Recruiting | Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NCT04140526 | OncoC4, Inc. | Phase 1 / Phase 2 |
| Completed | PROState Pathway Embedded Comparative Trial NCT04400656 | Imperial College London | — |
| Completed | Enzalutamide Plus Talazoparib for the Treatment of Hormone Sensitive Prostate Cancer (ZZ-First) NCT04332744 | MedSIR | Phase 2 |
| Completed | PSMA-PET/MRI for Radiation Treatment Planning in Patients With Locally Metastatic Prostate Cancer: A Pilot Stu NCT04086966 | University of Alabama at Birmingham | Phase 1 |
| Terminated | Two TraCer PositROn EmiSSion Tomography ComBination for Efficacy EstimatiOn of Prostate Specific Membrane Anti NCT04085991 | Sir Mortimer B. Davis - Jewish General Hospital | Phase 2 |
| Active Not Recruiting | A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors NCT04478279 | Sapience Therapeutics | Phase 1 / Phase 2 |
| Active Not Recruiting | Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newl NCT04262154 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Unknown | imPlementing ROutine Molecular Characterization in Patients With Metastatic Castration Resistant ProstaTe Canc NCT04746300 | Radboud University Medical Center | — |
| Completed | PRAGMA (Prostate Radio Ablation Guided by Magnetic Resonance Imaging Acquisition) in Metastatic Prostate Cance NCT04220983 | Weill Medical College of Cornell University | N/A |
| Completed | Predictive fActors for toleraNce to Taxane Based CHemotherapy In Older adultS Affected by mEtastatic Prostate NCT05471427 | Azienda Ospedaliero-Universitaria Careggi | — |
| Unknown | Molecular Stratification Profiling Protocol in Metastatic Castration Resistant Prostate Cancer (mCRPC) - MAEST NCT03934164 | Institute of Cancer Research, United Kingdom | — |
| Terminated | A Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Participants With Advanced Prostate Can NCT04179864 | Epizyme, Inc. | Phase 1 / Phase 2 |
| Completed | Toward a Comprehensive Supportive Care Intervention for Older or Frail Men With mCRPC NCT04193657 | University Health Network, Toronto | — |
| Active Not Recruiting | Plasma Analysis for Response Assessment and to DIrect the manaGement of Metastatic Prostate Cancer NCT04067713 | University College, London | — |
| Unknown | Single Dose Radiotherapy (SDRT) With or Without Adjuvant Systemic Therapy for Oligometastatic Prostate Cancer NCT04031378 | Fundacao Champalimaud | Phase 2 |
| Unknown | Impact of Atorvastatin on Prostate Cancer Progression During ADT NCT04026230 | Tampere University Hospital | Phase 3 |
| Active Not Recruiting | Prostate-Specific Membrane Antigen (PSMA) PET Scans in People Prostate Cancer NCT04030338 | Memorial Sloan Kettering Cancer Center | — |
| Completed | The Role of Ga68-PSMA-11 PET Imaging in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy NCT03977610 | Chang Gung Memorial Hospital | N/A |
| Completed | I-131-1095 Radioligand Plus Enzalutamide vs Enzalutamide for mCRPC That Progressed During Abiraterone (ARROW). NCT03939689 | Progenics Pharmaceuticals, Inc. | Phase 2 |
| Recruiting | PRostate Cancer Plasma Integrative Multi-modal Evaluation NCT06981377 | Santa Chiara Hospital | — |
| Completed | A Study to Determine Frequency of DNA-repair Defects in Men With Metastatic Prostate Cancer NCT03871816 | Janssen Research & Development, LLC | — |
| Active Not Recruiting | Additional Treatments to the Local Tumour for Metastatic Prostate Cancer: Assessment of Novel Treatment Algori NCT03763253 | Imperial College London | Phase 2 |
| Terminated | Docetaxel Versus Cabazitaxel Post Abiraterone or Enzalutamide NCT03764540 | Centre hospitalier de l'Université de Montréal (CHUM) | Phase 2 |
| Active Not Recruiting | Prostate Cancer Monitoring Using [18F]DCFPyL and Blood Based Biomarkers NCT03585114 | Columbia University | Phase 2 |
| Completed | Intramuscular Mechanisms of Androgen Deprivation-related Sarcopenia NCT03867357 | Seattle Institute for Biomedical and Clinical Research | — |
| Completed | COMbination of Bipolar Androgen Therapy and Nivolumab NCT03554317 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 |
| Active Not Recruiting | Standard Treatment +/- SBRT in Solid Tumors Patients With Between 1 and 5 Bone-only Metastases NCT03143322 | UNICANCER | N/A |
| Withdrawn | Phase I Trial of PACE for Metastatic Prostate Cancer NCT03110588 | University of Alabama at Birmingham | Phase 1 |
| Terminated | Cannabis Oil and Radiation Therapy for the Management of Pain NCT03763851 | Tetra Bio-Pharma | Phase 2 |
| Unknown | Radium-223 Combined With Dexamethasone as First-line Therapy in Patients With M+CRPC NCT03432949 | University Health Network, Toronto | Phase 4 |
| Completed | Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Def NCT03248570 | University of California, San Francisco | Phase 2 |
| Enrolling By Invitation | 18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer NCT03181867 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednison NCT03072238 | Hoffmann-La Roche | Phase 3 |
| Active Not Recruiting | 18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer NCT03173924 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Evaluation of the NantHealth GPS Cancer Test in Patients With Advanced Cancers NCT03073473 | Cota Inc. | — |
| Unknown | Cabazitaxel in mCRPC Patients With AR-V7 Positive Circulating Tumor Cells (CTCs) NCT03050866 | Erasmus Medical Center | Phase 2 |
| Terminated | Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumo NCT02744287 | Regeneron Pharmaceuticals | Phase 1 |
| Completed | One-year, Open Extension to Evaluate the Treatment of Patients With Castration-Resistant Prostate Cancer With NCT02962284 | Sun Pharmaceutical Industries Limited | Phase 2 |
| Unknown | Study of Natural Killer Cells in Patients With Metastatic Prostate Cancer: Relationship With Survival and Resp NCT02963155 | Institut Paoli-Calmettes | N/A |
| Completed | Evaluation of 18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer. NCT03497377 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 1 |
| Completed | Dose Escalating Study of Foxy-5 in Breast-, Colon- or Prostate Cancer Patients NCT02655952 | WntResearch AB | Phase 1 |
| Terminated | Enzalutamide and Niraparib in the Treatment of Metastatic Castrate-Resistant Prostate Cancer (CRPC) NCT02500901 | Paul Mathew, MD | Phase 1 |
| Recruiting | Cytoreductive Prostatectomy Combined With Triple or Dual Systemic Therapy in mHSPC Patients NCT06350825 | The First Affiliated Hospital with Nanjing Medical University | Phase 3 |
| Active Not Recruiting | INTense ExeRcise for SurviVAL Among Men with Metastatic Prostate Cancer (INTERVAL - GAP4) NCT02730338 | Movember Foundation | N/A |
| Completed | Observational Cohort Study of Patients With Castration-Resistant Prostate Cancer (CRPC) NCT02380274 | Astellas Pharma Global Development, Inc. | — |
| Completed | Non-Randomized Trial Assessing Pain Efficacy With Radium-223 in Symptomatic Metastatic Castration-Resistant Pr NCT02278055 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | Expanded Access to Diagnostic Imaging for Staging of Recurrent Prostate Cancer NCT02260817 | Global Isotopes, LLC d/b/a Zevacor Molecular | Phase 3 |
| Terminated | A Study in Patients With Metastatic Prostate Cancer to Assess How the Drug Eligard®, Affects Certain Markers i NCT01933022 | Astellas Pharma Europe Ltd. | Phase 4 |
| Active Not Recruiting | Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks NCT02051218 | Swiss Cancer Institute | Phase 3 |
| Withdrawn | Prospective Evaluation of Stereotactic Body Radiotherapy for Metastatic Prostate Cancer NCT02206724 | Sharp HealthCare | N/A |
| Completed | Study of 18F-DCFPyL, a Second Generation Low-molecular Weight PSMA-based PET Radiotracer, in Patients With Pro NCT02151760 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 1 |
| Completed | Abiraterone Acetate in Combination With Docetaxel After Disease Progression to Abiraterone Acetate in Metastat NCT02036060 | Spanish Oncology Genito-Urinary Group | Phase 2 |
| Unknown | Phase 1-2 Study of Onapristone in Patients With Advanced Castration-resistant Prostate Cancer NCT02049190 | Arno Therapeutics | Phase 1 / Phase 2 |
| Completed | A Study to Describe Patterns of Care and Outcomes of Men Who Are at High Risk After Experiencing Biochemical F NCT02066961 | Astellas Pharma Global Development, Inc. | — |
| Active Not Recruiting | A Phase III Study for Patients With Metastatic Hormone-naïve Prostate Cancer NCT01957436 | UNICANCER | Phase 3 |
| Completed | A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate NCT01981122 | Dendreon | Phase 2 |
| Completed | Phase I/IIA Study of PET Imaging With 89Zr-Df-IAB2M in Metastatic Prostate Cancer NCT01923727 | ImaginAb, Inc. | Phase 1 / Phase 2 |
| Completed | Impact of the Addition of Metformin to Abiraterone in Metastatic Prostate Cancer Patients NCT01677897 | Kantonsspital Graubünden | Phase 2 |
| Unknown | The Association Between Alpha 1 Acid Glycoprotein Level and Outcome Metastatic Cancer Treated With Docetaxel NCT01814150 | Gottfried Maya | — |
| Completed | Evaluation of 18F-DCFBC PSMA-based PET Imaging for Detection of Metastatic Prostate Cancer NCT01815515 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 1 / Phase 2 |
| Completed | Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate Cancer NCT01560923 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Completed | Second-line Chemotherapy in Castration Resistant Prostate Cancer NCT01558219 | Tampere University Hospital | Phase 2 |
| Completed | Anti-OX40, Cyclophosphamide (CTX) and Radiation in Patients With Progressive Metastatic Prostate Cancer NCT01303705 | Providence Health & Services | Phase 1 |
| Completed | Biomarkers of Bone Resorption in Metastatic Prostate Cancer NCT01233557 | University of Aberdeen | — |
| Completed | Duration of Suppression of Bone Turnover Following Treatment With Zoledronic Acid in Men With Metastatic CRPC NCT01062503 | University Health Network, Toronto | — |
| Completed | Docetaxel With a Phytochemical in Treating Patients With Hormone Independent Metastatic Prostate Cancer NCT01012141 | Centre Jean Perrin | Phase 2 |
| Completed | A Phase 2 Trial of Bevacizumab, Lenalidomide, Docetaxel, and Prednisone (ART-P) for Treatment of Metastatic Ca NCT00942578 | National Cancer Institute (NCI) | Phase 2 |
| Withdrawn | Human Telomerase Reverse Transcriptase Messenger RNA (hTERT mRNA) Transfected Dendritic Cell Vaccines NCT01153113 | University of Florida | Phase 1 / Phase 2 |
| Completed | Study of Dasatinib and Docetaxel in Metastatic Hormone Refractory Prostate Cancer NCT00439270 | Bristol-Myers Squibb | Phase 1 / Phase 2 |
| Terminated | Mitoxantrone, Prednisone Plus Sorafenib in Taxane-Refractory Metastatic Hormone Refractory Prostate Cancer (HR NCT00452387 | Accelerated Community Oncology Research Network | Phase 2 |
| Completed | Phase II Sunitinib Prog Met AIPC NCT00599313 | US Oncology Research | Phase 2 |
| Recruiting | Collection of Blood From Patients With Prostate Cancer NCT00923221 | National Cancer Institute (NCI) | — |
| Unknown | Safety Study of a Radiolabeled Antibody (7E11) in Patients With Progressive Hormone Refractory Prostate Cancer NCT00441571 | Cytogen Corporation | Phase 1 |
| Completed | ZANTE: Zometa and Taxotere in Hormone Refractory Prostate Cancer NCT00415779 | National Cancer Institute, Naples | Phase 1 |
| Terminated | Phase II Trial of Docetaxel and Celecoxib in Patients With Androgen Independent Prostate Cancer NCT00494338 | Sanofi | Phase 2 |
| Withdrawn | CMAB vs IMAB in Metastatic Prostate Cancer NCT00255268 | AstraZeneca | Phase 4 |
| Completed | Safety and Efficacy Study of of Docetaxel vs Docetaxel Estramustine in Hormone Refractory Prostatic Cancer NCT00541281 | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | Phase 2 |
| Completed | PROSTACOX : Metastatic Prostate Chemotherapy NCT00213694 | University Hospital, Rouen | — |
| Terminated | Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal NCT00216060 | Christopher Sweeney, MBBS | Phase 3 |
| Terminated | Antineoplaston Therapy in Treating Patients With Metastatic Prostate Cancer NCT00003533 | Burzynski Research Institute | Phase 2 |